These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34221384)

  • 21. Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.
    Molony DA; Parameswaran V; Ficociello LH; Mullon C; Kossmann RJ
    Kidney360; 2020 Apr; 1(4):263-272. PubMed ID: 35372921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.
    Koiwa F; Yokoyama K; Fukagawa M; Terao A; Akizawa T
    Nephrology (Carlton); 2017 Apr; 22(4):293-300. PubMed ID: 27496336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Floege J
    Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
    Yoshida T; Morimoto K; Kaburagi N; Fujino T; Takemitsu TY; Yamashita N; Oya M
    Int Urol Nephrol; 2022 Apr; 54(4):861-872. PubMed ID: 34264473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease in Asturias. FOSFASTUR study.
    Sanchez-Alvarez JE; Astudillo Cortés E; Seras Mozas M; García Castro R; Hidalgo Ordoñez CM; Andrade López AC; Ulloa Clavijo C; Gallardo Pérez A; Rodríguez Suarez C
    Nefrologia (Engl Ed); 2021; 41(1):45-52. PubMed ID: 36165361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort.
    Kendrick JB; Zhou M; Ficociello LH; Parameswaran V; Mullon C; Anger MS; Coyne DW
    Int J Nephrol Renovasc Dis; 2022; 15():139-149. PubMed ID: 35431567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide.
    Gray K; Ficociello LH; Hunt AE; Mullon C; Brunelli SM
    Int J Nephrol Renovasc Dis; 2019; 12():1-8. PubMed ID: 30774412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
    Sprague SM; Covic AC; Floege J; Ketteler M; Botha J; Chong EM; Rastogi A
    Am J Nephrol; 2016; 44(2):104-12. PubMed ID: 27434393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study.
    Kalantar-Zadeh K; Ficociello LH; Parameswaran V; Athienites NV; Mullon C; Kossmann RJ; Coyne DW
    BMC Nephrol; 2019 Oct; 20(1):396. PubMed ID: 31664928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Ketteler M
    Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.
    Covic AC; Floege J; Ketteler M; Sprague SM; Lisk L; Rakov V; Rastogi A
    Nephrol Dial Transplant; 2017 Aug; 32(8):1330-1338. PubMed ID: 27342579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis.
    Medaura JA; Zhou M; Ficociello LH; Anger MS; Sprague SM
    Am J Nephrol; 2024; 55(2):127-135. PubMed ID: 38091973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study.
    Ferreira A; Pinto B; Navarro D; Aniceto J; Neves PL; Ponce P
    J Bras Nefrol; 2019; 41(2):224-230. PubMed ID: 30742699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care.
    Rhee CM; Zhou M; Woznick R; Mullon C; Anger MS; Ficociello LH
    Int Urol Nephrol; 2023 Feb; 55(2):377-387. PubMed ID: 35953565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis.
    Perez L; You Z; Teitelbaum I; Andrews ES; Reddin R; Ramirez-Renteria L; Wilson G; Kendrick J
    BMC Nephrol; 2022 Jul; 23(1):245. PubMed ID: 35810296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide.
    Stavroulopoulos A; Aresti V; Papadopoulos C; Nennes P; Metaxaki P; Galinas A
    World J Nephrol; 2018 Oct; 7(6):123-128. PubMed ID: 30324087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.
    Koiwa F; Yokoyama K; Fukagawa M; Akizawa T
    Kidney Int Rep; 2018 Jan; 3(1):185-192. PubMed ID: 29340330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
    Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients.
    Lioulios G; Stangou M; Sarafidis PA; Tsouchnikas I; Minasidis I; Vainas A; Faitatzidou D; Sampani E; Papagianni A
    Blood Purif; 2020; 49(4):440-447. PubMed ID: 32050202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease.
    Sampson M; Faria N; Powell JJ;
    Nephrol Dial Transplant; 2021 Jul; 36(8):1399-1407. PubMed ID: 32651955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.